<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739310</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0088</org_study_id>
    <nct_id>NCT00739310</nct_id>
  </id_info>
  <brief_title>Study Assessing High-Frequency Chest Wall Oscillation (HFCWO) in Preventing Pulmonary Exacerbations</brief_title>
  <official_title>A Pilot Study to Assess the Efficacy and Effectiveness of High-Frequency Chest Wall Oscillation (HFCWO) in Preventing Pulmonary Exacerbations in Children With Muscle Weakness and Restrictive Lung Disease CR-0088</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hill-Rom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hill-Rom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To asssess efficacy of airway clearance provided by Vest therapy (HFCWO) in the reduction of
      respiratory exacerbations requiring hospitalization or antibiotic utilization in patients
      with muscle weakness and restrictive lung disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-randomized home based pre-post intervention study. The study will compare the
      efficacy of VestÂ® therapy (HFCWO) for mucus secretion clearance in a population of patients
      with muscle weakness and restrictive lung disease with frequent pulmonary exacerbations.
      Enrolled subjects with a tracheostomy will be evaluated for microbial load and inflammatory
      status as a pilot evaluation of microbial load and inflammatory status outcomes.

      The total number of evaluable subjects to be recruited is estimated at 40. Subjects will be
      considered evaluable if they have completed at least 6 months of follow up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalizations Lasting at Least 24 Hours in This Patient Population</measure>
    <time_frame>end of study</time_frame>
    <description>Hospitalizations lasting at least 24 hours</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Vest Treatment (HFCWO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Vest treatments for airway clearance therapy 2 x daily for 12 months. These data will be compared to 12 months of data prior to Vest initiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vest Treatment (high frequency chest wall oscillation)</intervention_name>
    <description>twice daily for 15-20 minutes</description>
    <arm_group_label>Vest Treatment (HFCWO)</arm_group_label>
    <other_name>HFCWO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is at least 18 months old.

          -  Subject has a chest circumference of greater than 19 inches.

          -  Subject has a diagnosis of muscle weakness and restrictive lung disease.

          -  Ability to provide Informed consent from legal guardian.

          -  Subject has had 2 or more exacerbations requiring either hospitalization or
             antibiotics (IV or oral) in the past 12 months

          -  If inhaled Tobramycin has been prescribed prophylacticly, subjects must discontinue
             the medication at least 2 weeks prior to study enrollment

        Exclusion Criteria:

          -  Subject has a diagnosed allergy with a respiratory trigger.

          -  Participation in another clinical trial.

          -  Unstable head or spinal injury.

          -  Unresolved pneumothorax or pneumomediastinum present

          -  Unresolved hemorrhage

          -  Hypotension requiring vasopressors or positioning

          -  Bronchopleural fistula

          -  Gross hemoptysis within the past eight hours

          -  Pulmonary embolism or history of pulmonary embolism within the past two months

          -  Burns, open wounds and skin infections on the thorax

          -  Osteomyelitis of the ribs

          -  Osteoporosis with history of fractures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikail Kazachkov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <results_first_submitted>April 20, 2015</results_first_submitted>
  <results_first_submitted_qc>August 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2015</results_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Frequency Chest Wall Oscillation</keyword>
  <keyword>Cerebral Palsy</keyword>
  <keyword>Restrictive lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vest Treatment (HFCWO)</title>
          <description>Patients will receive Vest treatments for airway clearance therapy 2 x daily
Vest Treatment (high frequency chest wall oscillation): twice daily for 15-20 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Poor adherance to prescribed therapy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients who completed 12 months of prospective therapy</population>
      <group_list>
        <group group_id="B1">
          <title>Vest Treatment (HFCWO)</title>
          <description>Patients will receive Vest treatments for airway clearance therapy 2 x daily for 12 months. These data will be compared to 12 months of data prior to Vest initiation.
Vest Treatment (high frequency chest wall oscillation): twice daily for 15-20 minutes</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.55" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospitalizations Lasting at Least 24 Hours in This Patient Population</title>
        <description>Hospitalizations lasting at least 24 hours</description>
        <time_frame>end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Treatment</title>
            <description>Prior to Vest Treatment</description>
          </group>
          <group group_id="O2">
            <title>Post Vest Treatment</title>
            <description>12 months of intervention 2 x daily Vest Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations Lasting at Least 24 Hours in This Patient Population</title>
          <description>Hospitalizations lasting at least 24 hours</description>
          <units>hospitalizations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vest Treatment (HFCWO)</title>
          <description>Patients will receive Vest treatments for airway clearance therapy 2 x daily
Vest Treatment (high frequency chest wall oscillation): twice daily for 15-20 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study design was sub-optimal due to lack of control group and lack of randomization</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathryn Fitzgerald, NP</name_or_title>
      <organization>Maimonides, Department of Pulmonary Medicine</organization>
      <phone>718-283-7339</phone>
      <email>kfitzgerald@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

